Trial 24, one of three ongoing trials in the Early Prostate Cancer programme, is evaluating the efficacy and tolerability of bicalutamide (Casodex) 150 mg following standard care (radiotherapy, radical prostatectomy or watchful waiting) in patients with early, non-metastatic prostate cancer. At 7 years' median follow-up, addition of bicalutamide significantly improved objective progressionfree survival (PFS) for patients with locally advanced disease, reducing the risk of progression by 34% versus standard care alone (hazard ratio 0.66; 95% confidence interval 0.55, 0.79; Po0.001). In localized disease, a significant difference in objective PFS was not found. There was no significant difference in overall survival.
Introduction
For men with prostate cancer, disease progression has serious physical and emotional consequences, including painful bone metastases, urinary dysfunction and depression. 1 Early evidence of disease progression, such as a rising prostate-specific antigen (PSA) level, is also associated with considerable psychological distress for patients and their relatives 2 and can increase economic burden. 3 It is, therefore, important that patients are offered effective therapies that can delay disease progression.
Androgen deprivation is increasingly being used in men with non-metastatic disease or recurrent disease after therapy of curative intent (i.e. radical prostatectomy or radiotherapy), particularly in those patients with a high risk of recurrence or progression. Castration-based therapy is the predominant form of androgen deprivation therapy and the luteinizing hormone-releasing hormone agonist (LHRHa), goserelin (Zoladex, AstraZeneca, Macclesfield, UK), is the most widely studied. In patients with locally advanced disease, goserelin adjuvant to radiotherapy has been shown to significantly improve overall survival compared with radiotherapy alone. 4, 5 Castration-based therapy with goserelin or orchiectomy adjuvant to radical prostatectomy has also been shown to significantly improve overall survival in locally advanced patients with lymph nodepositive disease compared with radical prostatectomy alone. 6, 7 LHRHas are, however, associated with loss of libido, decreased muscle mass and loss of bone mineral density. 8, 9 These adverse effects are manageable in most patients 8 but, as prostate cancer is now being diagnosed at an earlier stage and in younger men than ever before, 10 there is an emphasis on the need for treatment options that enable patients to maintain quality of life. Non-steroidal antiandrogens have emerged as an attractive alternative to castration because they have been shown to offer comparable survival to castration therapy in locally advanced disease, but are less frequently associated with loss of sexual activity and physical capacity. 8, 11, 12 The European Association of Urology Guidelines on Prostate Cancer state that of the three available non-steroidal antiandrogens, bicalutamide (Casodex, AstraZeneca, Macclesfield, UK) demonstrates a more favourable safety and tolerability profile than nilutamide or flutamide. 13, 14 The ongoing Early Prostate Cancer (EPC) programme is investigating the effects of adding bicalutamide 150 mg/day to standard care (radiotherapy, radical prostatectomy or watchful waiting). This study recruited 8113 men with localized (T1-2, N0 or Nx, M0) or locally advanced (T3-4, any N, M0 or any T, N þ , M0) prostate cancer. 12 Updated results of the overall programme at 7.4 years' median follow-up have recently been published. 12 The EPC programme comprises three, double-blind, randomized, placebo-controlled trials (Trials 23, 24 and 25), which were prospectively designed for a stratified, combined analysis. Trial 23 was conducted in North America; Trial 24 in Europe, Mexico, South Africa, Israel and Australia; and Trial 25 in Scandinavia. Previous analyses of Trial 24 15, 16 and the overall EPC programme 12, 17, 18 have shown that bicalutamide significantly reduces the risk of disease progression, particularly in patients with locally advanced disease. There was no significant difference in the overall survival at the most recent analysis of the overall programme. 12 Here, we report the updated results from Trial 24 at 7 years' median follow-up.
Methods
The methodology for Trial 24 has been described previously 16, 19 and is, therefore, presented here in brief.
Trial design
Trial 24 is a randomized, double-blind, placebo-controlled trial. A total of 3603 patients were recruited into this trial between September 1995 and July 1998 from 191 centres.
Men with clinically or pathologically confirmed stage T1b-T4, any N, M0 prostate cancer were included in the trial. Following standard care, eligible patients were randomized 1:1 to receive oral bicalutamide 150 mg once daily or matching placebo. For patients receiving radical prostatectomy or radiotherapy as their standard care, the recommended duration of treatment was 5 years or until objective disease progression if this occurred sooner. For patients undergoing watchful waiting, it was recommended that randomized therapy should continue until objective disease progression with no maximum duration of therapy. Upon disease progression, trial bicalutamide 150 mg or placebo was withdrawn and alternative therapy was initiated at the investigators' discretion. All patients are being followed until objective progression or death.
Following the second analysis of the overall EPC programme, 18 the independent data and safety committee and the trial steering committee recommended that randomized trial therapy be discontinued, that investigators and patients be informed of the findings, and that the treatment code be broken for all patients. For patients still receiving randomized therapy at the time, the treatment code was broken, investigators, at their discretion and on discussion with their patient, had the option to start patients on open-label bicalutamide 150 mg, switch patients to an alternative therapy or continue without any therapy.
The trial was conducted in accordance with the Declaration of Helsinki and Good Clinical Practice guidelines, and with the approval of the Independent Ethics Committee or Institutional Review Board at each centre.
Assessments and end points
Following randomization, patients were assessed at 12-weekly intervals for local and regional disease, distant metastases, clinical symptoms, PSA levels, liver biochemistry and other clinical laboratory parameters. Bone scans were carried out pretrial and every 96 weeks thereafter. After therapy withdrawal, patients were followed every 24 weeks until death.
The primary end points for Trial 24 were objective progression-free survival (PFS) and tolerability. The secondary end points included overall survival and PSA progression-free survival (PSA PFS).
Statistical analyses
The statistical analysis was performed at 7 years' median follow-up, using methods that have been described previously. 15, 16 Briefly, the time-to-event end points for the overall Trial 24 population were analysed on an intent-to-treat basis using a Cox proportional hazards regression model, with covariates for randomized treatment, baseline PSA level, Gleason score, disease stage and primary treatment of curative intent. This model estimates the hazard ratio (HR; bicalutamide:standard care alone), with the associated 95% confidence intervals (CI) and P-value. Tolerability was assessed according to the randomized treatment received.
Results

Patients
A total of 3603 patients in Trial 24 were randomized to receive standard care plus either bicalutamide 150 mg (n ¼ 1798) or placebo (n ¼ 1805). The two treatment groups were well balanced with respect to patient demography and baseline disease characteristics ( Table 1 ). The median follow-up of the analysis was 7 years. No patients were still receiving randomized therapy at the time of the analysis.
Efficacy
Overall survival. In Trial 24, 26.5% (476/1798) of the patients randomized to receive bicalutamide 150 mg in addition to standard care and 26.6% (481/1805) of those randomized to receive standard care alone had died. There was no significant difference in overall survival between the two treatment arms in the entire Trial 24 population (HR 1.00; 95% CI 0.88, 1.14; P ¼ 0.946) ( Figure 1) .
Analysis of the Trial 24 population by disease stage revealed that there was no significant difference in overall survival between the treatment groups for patients with localized or locally advanced disease. In patients with localized disease, 25.7% of patients who (Figure 2 ). The PFS benefit seen in the overall Trial 24 population was dependant upon disease stage. In patients with localized disease, there was no significant difference in PFS between the two treatment arms (HR 0.88; 95% CI 0.76, 1.03; P ¼ 0.104). However, in patients with locally advanced disease, bicalutamide significantly improved objective PFS, reducing the risk of objective disease progression by 34% versus standard care alone (HR 0.66; 95% CI 0.55, 0.79; Po0.001) (Figure 3 ).
Prostate-specific antigen progression-free survival. At the time of this analysis, 41.2% (740/1798) of patients receiving bicalutamide 150 mg in addition to standard care and 56.3% (1016/1805) of patients receiving standard care alone had met the criteria for PSA progression. Bicalutamide plus standard care significantly reduced the risk of PSA progression in the overall Trial 24 population by 49% compared with standard care alone (HR 0.51; 95% CI 0.46, 0.56; Po0.001) (Figure 4 ). The PSA PFS benefit associated with addition of bicalutamide to standard care was seen both in patients with localized disease (HR 0.55; 95% CI 0.49, 0.62; Po0.001) and 
Additional therapy
At the discretion of the investigators, trial bicalutamide 150 mg or placebo could be stopped and patients could be offered additional therapy. Overall, 27.9 and 50.0% of patients received additional systemic therapy in the bicalutamide 150 mg and standard care alone arms, respectively; radiotherapy was given to 2.4 and 3.8% of patients in the bicalutamide and standard care alone arms, respectively. In both treatment arms, the most commonly used systemic therapy was antiandrogen treatment: 12.8% of patients in the bicalutamide arm received additional antiandrogen and, in the standard care alone arm, 16.7% of patients received an antiandrogen, and a further 10.4% received open-label bicalutamide 150 mg. Castration was given to 11.2% of patients in the bicalutamide arm and 15.1% of patients in the standard care alone arm.
Tolerability and safety
The most commonly reported adverse effects in patients who received bicalutamide 150 mg plus standard care were gynaecomastia (68.7% (1230/1790)) and breast pain (66.3% (1187/1790)) ( Table 2 ). These effects were mild to moderate in severity in the majority of cases (485%). The incidences of other reported adverse effects were low in both treatment arms (Table 2 ) and included hot flushes (9.6 versus 4.8% for bicalutamide plus standard care and standard care alone, respectively), impotence (8.4 and 6.1%, respectively), decreased libido (2.6 and 0.6%, respectively) and abnormal liver function tests (2.1 and 0.8%, respectively).
The withdrawals towing to adverse effects were 30.6% (547/1790) with bicalutamide 150 mg plus standard care Table 3 ). The observed increase in nonprostate cancer-related deaths with bicalutamide appears to be due to a number of small imbalances rather than a specific cause.
Discussion
Data from this third planned analysis of Trial 24 (at 7 years' median follow-up) continue to show that bicalutamide 150 mg given in addition to standard care significantly improves PSA PFS and objective PFS with no significant difference in survival. When the results are considered by disease stage, patients with locally advanced disease demonstrate a significant improvement in PSA PFS or objective PFS, but not in overall survival. In the subgroup of patients with localized disease, addition of bicalutamide to standard care provides no significant benefit in terms of objective PFS or overall survival.
As Trial 24 is one of three trials within the EPC programme, it is important to consider the results in the context of both the overall EPC programme and the two accompanying trials (Trial 23 and Trial 25, also known as SPCG-6).
Trial 25 is being conducted in Scandinavia, where more than 80% of patients underwent watchful waiting as standard care. In patients with localized disease in the watchful waiting group of Trial 25, there was a trend towards decreased overall survival with bicalutamide versus watchful waiting (HR 1.18; 95% CI 0.91, 1.54; P ¼ 0.22). 20 Conversely, among patients with locally advanced disease who would otherwise have undergone watchful waiting, bicalutamide 150 mg significantly improved overall survival, reducing the risk of death by 33% compared with watchful waiting (HR 0.67; 95% CI 0.50, 0.90; P ¼ 0.007).
In contrast to Trial 25, the statistical interaction test between randomized treatment and the pre-specified baseline prognostic factors on overall survival in Trial 24 was not significant (P ¼ 0.50), suggesting that, within Trial 24, baseline prognostic factors, such as disease stage, did not influence the effect of bicalutamide on overall survival. However, given the findings from Trial 25, it is important to investigate whether a similar trend is seen in the watchful waiting patients of Trial 24 (there were no watchful waiting patients in Trial 23). Among patients in Trial 24 with localized disease who would otherwise have undergone watchful waiting, bicalutamide 150 mg was associated with a trend towards decreased overall survival compared with standard care alone that was similar to that seen in Trial 25 (HR 1.15; 95% CI 0.93, 1.42; P ¼ 0.19). However, in contrast to Trial 25, patients in Trial 24 with locally advanced disease who would otherwise have undergone watchful waiting showed no difference in overall survival between treatment arms (HR 0.98; 95% CI 0.71, 1.35; P ¼ 0.91). Therefore, whereas the survival results for patients in the watchful waiting population who had localized disease are consistent between Trials 24 and 25, the results differ for patients with locally advanced disease.
The differences in overall survival outcome between Trials 24 and 25 for patients with locally advanced disease in the watchful waiting group could be a consequence of the better prostate cancer prognosis of patients in Trial 24. For example, patients in Trial 24 had a lower median PSA level before randomization than patients in Trial 25 (11.4 versus 17.2 ng/ml) and, at the latest analysis, a lower proportion of patients with locally advanced disease had died owing to prostate cancer (34 versus 65%, respectively). Furthermore, the potential candidates for watchful waiting are likely to have been The findings from Trial 24 and the overall EPC programme indicate that addition of bicalutamide 150 mg to standard care offers clinical benefit to patients with locally advanced prostate cancer. Patients with localized disease do not appear to derive benefit from the addition of bicalutamide 150 mg to standard care and this is, therefore, not recommended for such patients.
Additional therapy was given to a high proportion of patients in both the bicalutamide arm (27.9%) and the standard care alone arm (50.0%). The majority of these patients received systemic therapy using antiandrogens or castration, but some received radiotherapy, oestrogen or chemotherapy. Although the trial protocol was designed with the expectation that patients would change therapy following clinical progression, additional therapy was given at the discretion of the investigators and many patients received treatment in response to a rise in PSA. This is illustrated by the fact that the proportion of patients randomized to standard care alone who received additional systemic therapy was similar to the proportion who experienced a PSA progression event (50.0 versus 56.3%, respectively) and higher than the proportion who experienced objective progression (50.0 versus 36.1%, respectively). Generally, the introduction of hormonal therapy occurred earlier in this trial than in studies investigating adjuvant castration; 4, 6 however, the more frequent and earlier introduction of hormonal therapy in this study is in keeping with current trends in clinical practice. The early use of hormonal therapy in response to rising PSA is likely to reduce the extent of any treatment effect in terms of objective progression-free and overall survival; however, it is not possible to quantify this effect.
The safety and tolerability data of Trial 24 were consistent with previous analyses. 15, 16 The most frequently reported adverse effects with bicalutamide 150 mg were gynaecomastia and breast pain, which are commonly associated symptoms of non-steroidal antiandrogen treatment and led to withdrawal of 18% of patients.
In conclusion, there was no benefit seen in Trial 24 in patients with localized disease receiving bicalutamide plus standard care versus standard care alone. Furthermore, the finding in the overall EPC programme analysis of a trend towards a survival deficit in patients with localized disease who would otherwise have undergone watchful waiting was also seen within Trial 24 itself. Therefore, bicalutamide is not recommended for patients with localized disease.
Consistent with the findings from previous analyses of Trial 24 15 and the EPC programme as a whole, 12, 17, 18 these more mature data from Trial 24 demonstrate that bicalutamide 150 mg in addition to standard care significantly improves objective PFS and PSA PFS in patients with locally advanced disease compared with standard care alone. However, there was no significant difference in overall survival between the two treatment arms in patients with locally advanced disease.
In the overall EPC analysis, there was a trend towards an improvement in overall survival in patients with locally advanced disease who would otherwise have undergone watchful waiting; however, this was not seen within Trial 24 itself. Nevertheless, data from Trial 24 do contribute to the significant finding seen in the overall EPC analysis that bicalutamide 150 mg adjuvant to radiotherapy improves overall survival versus radiotherapy alone. In summary, bicalutamide remains a valuable and effective hormonal treatment option in patients with locally advanced disease.
